A review was published in The Lancet The safety and efficacy record of billions of mRNA Covid vaccine doses was read out on Tuesday. The headline finding is not surprising: The platform is safe and offers life-saving protection, with rare adverse events now being characterized and far beyond what the vaccines prevent. “During the COVID-19 pandemic, mRNA vaccines demonstrated what rapid, science-driven collaboration can achieve,” said Anna Blakeney, an immunologist at the University of British Columbia who led the review.
But the importance of the review is not to declare the matter resolved. It reads the record carefully – what was safe, what side effects emerged, whether the biological mechanism was at work in any case – at a time when mRNA platforms are rapidly moving beyond Covid into vaccines against flu and RSV, personalized cancer treatments and treatments for genetic diseases like sickle cell.
What does mRNA vaccine do in the body?
It is worth understanding the mechanism precisely, as most of the concerns about mRNA vaccines are based on misconceptions about what they do in the body. An mRNA vaccine delivers a small portion of synthetic genetic instructions wrapped in a fatty bubble called a lipid nanoparticle into the cytoplasm of muscle cells at the injection site. The cytoplasm is the outer part of the cell – not the nucleus, where the DNA lives. The cellular machinery reads the instructions, makes a copy of the virus’s spike protein, and is trained by that protein to recognize and fight the real virus. The spike can be detected for about seven days. In animal studies the mRNA and lipid components are cleared through the kidneys and liver within three to seven days.
The review outlines the formal regulatory distinction in detail: Gene therapy involves the intentional and permanent alteration of a patient’s genome. There are no mRNA vaccines. The two are separate categories, and mixing them is one of the most enduring misinformation about these supplements.
Another mechanism is technological progress that is directly related to security. The lipids in the two authorized mRNA Covid vaccines are what scientists say are ionizable rather than permanently cationic. They are electrically neutral at the normal pH of the body, being charged only inside the acidic compartments of cells where the cargo needs to be released. Earlier delivery systems always used charged lipids which damaged cell membranes and caused inflammation. New people don’t do this.
Billions of doses have established what
The safety-monitoring record — the system that tracks side effects after a vaccine moves from clinical trials to everyday use — is where most of the open questions have been answered.
Serious allergic reactions – anaphylaxis – occur in about two to eight people per million doses, and most of those who react can be safely re-vaccinated under supervision. The blood-clotting syndrome that has emerged in some cases with adenoviral-vector vaccines like Covishield has not been seen with mRNA vaccines.
A highly controversial side effect produced by this platform, and the one that has been most carefully studied, is inflammation of the heart muscle or its outer layer – myocarditis and pericarditis. The risk increases three weeks after vaccination and peaks in the first week – but mostly in boys and young men aged 12 to 29.
The finding that matters for the risk-benefit calculation is that the risk of heart inflammation from the vaccine is much lower than the risk of Covid infection itself, and most vaccine-associated cases have been clinically mild. A subgroup of patients report symptoms persisting for more than a year, and the review states that long-term follow-up is necessary.
Two recent studies cited in the review fill out the picture in finer detail. 2025 The Danish group tracked one million vaccinated adults across 29 potential adverse events and found no significant risk in the four weeks after vaccination. In a US analysis of 244,494 adults who received an XBB.1.5-adapted booster, looking at 15 adverse events, only anaphylaxis was found to be statistically associated. One documented person received 217 mRNA Covid vaccinations without any adverse events.
which remains open
The writers are equally clear about what remains open. After a booster dose, the immune system shifts to producing a particular type of antibody called IgG4 – ranging from about 0.04% of the antibody response to as much as 19% in some measurements. These antibodies still bind to the virus and neutralize it. What they do less good is summon the rest of the immune system’s cleaning machinery to destroy infected cells. The clinical meaning has not yet been determined. The same change has been observed in repeated dose trials of non-mRNA vaccines against HIV, malaria and pertussis, suggesting that this is a feature of giving the body the same antigen multiple times, and not something specific to mRNA. It may also reduce inflammation-induced tissue damage. The honest answer is that scientists are still working on it.
The platform also has a built-in limitation. The mRNA vaccine injected into the muscle produces strong immunity throughout the body, but weak immunity in the moist linings of the nose and throat – where the respiratory virus first enters. This is why mRNA Covid vaccines reduce severe disease and transmission, but do not prevent the vaccinated person from getting infected and spreading the virus. The same mismatch explains why protection from infection wanes faster than protection from hospitalization, and why boosters continue to be recommended.
The platform also isn’t going to fix everything. As the review states, “mRNA vaccines are not a panacea for all ills”. Moderna’s RSV vaccine, MRESVIA, received FDA approval in May 2024 for adults ages 60 and older, with expanded approval in 2025 for at-risk younger adults. A separate program for infants was halted after safety signals in infants ages five to seven months, and Moderna abandoned the kind of course-correction that has been integral to the science. Pfizer’s mRNA flu vaccine outperformed the standard flu shot in adults ages 18 to 64 in a trial published in. New England Journal of Medicine last November. The same test performed poorly in a different group of older adults.
In other words, the technology works but whether every vaccine built on it works is a different question, and one that will remain to be answered over the next decade.
The stage and its people
A platform that works is one thing. The public that will accept its products is another matter. The review notes UNICEF’s findings that 52 out of 55 countries reported a decline in vaccine confidence during the Covid pandemic – 94 per cent. A 2023 sentiment analysis of approximately 750,000 social-media posts on mRNA technology found widespread negative perceptions about the platform’s safety, effectiveness, and reliability, as well as what the review’s authors described as frequent discussion of serious side effects, rumors, and misinformation. Before the pandemic, vaccine hesitancy was on WHO’s list of top ten global health threats in 2019. The pandemic accelerated this. The review’s authors note that misuse of passive reporting systems – voluntary databases like US VAERS, which collect unverified reports of any event following vaccination – to suggest causality where none is established has been a particular driver of disinformation that “destroys public trust and vaccine uptake.”
Drew Weissman, the immunologist at the University of Pennsylvania whose seminal work on modified mRNA earned him and his former colleague Caitlin Carico the 2023 Nobel Prize in Medicine, is publicly describing the fallout. “If you look back 250 years, 40 percent of our children around the world did not make it to adulthood. Nowadays it’s 4 percent and that’s mainly because of vaccines.” He told Hindustan Times in an interview last year. “The world is now starting to move away from vaccines, which means infectious diseases are going to be a bigger problem. Children are going to start dying from measles, polio and other diseases that we thought were gone.” Preventing measles outbreaks requires 95 percent population coverage. “Right now, 30 percent of people are refusing to get the vaccine,” Weissman said.
“In the old days, there were always anti-vaccine people, but they weren’t leading our governments. They weren’t in power. And now (they’re) idealizing anti-vaccine regulations.”
The author of the review arrives at the same place. “The widespread spread of misinformation and the politicization of the vaccine discussion,” they write, “threaten to erode trust in science-based medicine.”
About 11 percent of current mRNA clinical trials target cancer, including personalized vaccines that train the immune system against specific mutations in an individual patient’s tumor. About 30 percent of targeted therapeutic applications—which Weissman described to HT—are gene therapy programs, which provide “enzymes that can correct incorrect DNA sequences and genetic deficiencies like sickle cell or cystic fibrosis,” and therapeutic proteins for acute intervention: “If someone is having a stroke, we can deliver an anti-inflammatory protein to reduce inflammation in the brain.”
The next mRNA products are coming. Some will work and some, like the cytomegalovirus candidate, won’t. Some will reach readers as flu shots and some as cancer treatments. Clinical, manufacturing and regulatory questions are streamlined. The question is whether science is allowed to land or not. As Manish Sadarangani, senior author of the review at the BC Children’s Hospital Research Institute, said: “MRNA vaccines have already changed how we respond to emerging diseases, and with ongoing innovation and rigorous safety monitoring, they could lead to advances in preventive medicine and cancer treatment for years to come.”
